Regular inhaled salbutamol and asthma control: the TRUST randomised trial

Dennis, Sarah; Sharp, Stephen J.; Vickers, Martin; Frost, Chris; Crompton, G.K.; Barnes, Peter J.; Lee, Tak H.

doi:10.1016/s0140-6736(00)02238-8

Cited by 87 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For those via nebulizer: 2.5-5 mg, may repeat up to 4 times daily. Alternatively, may be given continuously at a rate of 1-2 mg/hr (Dennis et al, 2000).…”

Section: Monotherapymentioning

confidence: 99%

Retrospective studies on drug utilization patterns of asthmatics in a Government hospital in Kedah, Malaysia

et al. 2012

View full text Add to dashboard Cite

Retrospective DUE is the reviewing of drug therapy after the patient has received the medication. Asthma is a common chronic disease in Malaysia. A National Health and Morbidity Survey in 1996 indicated that asthma prevalence in Malaysia was 4.2%. Statistics on the causes of death have noted asthma as one of the 10 principal causes of death (7.3%) in Malaysia. The purpose of the study was to compare drug utilization patterns amongst the asthmatics from the past two years (since 2009) in Kedah state. Asthmatics admitted to the hospital in the preceding two years were analyzed by their patient charts. This study focused on both smoker and non smoker asthmatics. It was observed that salbutamol was most commonly prescribed, followed by montelukast and prednisolone. In the combination therapy, the most commonly prescribed was Symbicort, followed by seretide and combivent. Corticosteroids constituted the most prevalent class, followed by beta-2 agonists, leukotriene modifiers and methylxanthines. The study presented the most recent scenario on drug utilization pattern of asthmatics in Kedah state.DOI: http://dx.doi.org/10.3329/icpj.v1i11.12060 International Current Pharmaceutical Journal 2012, 1(11): 353-360

show abstract

“…For those via nebulizer: 2.5-5 mg, may repeat up to 4 times daily. Alternatively, may be given continuously at a rate of 1-2 mg/hr (Dennis et al, 2000).…”

Section: Monotherapymentioning

confidence: 99%

Retrospective studies on drug utilization patterns of asthmatics in a Government hospital in Kedah, Malaysia

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Albuterol Sulphate, the most widely prescribed bronchodilator in the United Kingdom on the control of asthma (Dennis et al, 2000) that is a fairly water soluble drug, well absorbed orally and throughout the gastrointestinal tract, and the peak plasma levels are attained within 1-3 h. It is extensively metabolized after oral administration mainly via conjugation mechanism and has biological half-life of about 4-6 h (Sweetman and Martindale, 2005). As a result of the quick absorption and short half-life, it is administered orally 3-4 times a day.…”

Section: Introductionmentioning

confidence: 99%

Effect of Kollidon® SR on the release of Albuterol Sulphate from matrix tablets

Sakr

Alanazi

Sakr

2011

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

The objective of this study was to evaluate Kollidon SR for the development of extended release Albuterol Sulphate matrix tablets in comparison with other polymers as Hydroxypropylmethylcellulose K15M, Carbopol 71G NF, and Eudragit L100-55. The mechanical properties of the tablets were improved as concentration of Kollidon SR or other polymers increased. It was found that Kollidon SR 30% (w/w) and HPMC 30% (w/w) tablets have f 2 similarity factor of 83.5 in their Albuterol Sulphate dissolution profile. The marketed product was found to release 99.7% of drug content within 8 h, while Kollidon SR and HPMC tablets with 30% (w/w) polymer concentration level released 92.7% and 92.9% respectively of drug content within 8 h. Kollidon SR has a unique character of maintaining tablets geometric shape until the end of dissolution test, this is mainly due to the water insoluble content, polyvinyl acetate, forming 80% (w/w) of Kollidon SR, while the remaining content 20% (w/w) is the water soluble, polyvinylpyrrolidone, responsible for pore formation causing a diffusion controlled release. Drug release from all previous formulations is best described to be controlled by more than one kinetic mechanism of release.In conclusion, Kollidon SR and HPMC and Carbopol were found to be potential candidates for the development of extended release of Albuterol Sulphate tablets.

show abstract

“…Although cardiac adverse events were frequently considered responsible for the increased risk, a 1-yr clinical trial showed increased airway responsiveness and worsened asthma control during regular treatment with fenoterol added to usual therapy AFFILIATIONS *Firestone Institute for Respiratory Health, St Joseph's Healthcare, and compared with b-agonist used only as needed for symptom relief [10,11]. However, subsequent US and UK trials of regular versus as needed salbutamol did not detect sustained adverse effects on asthma control [12,13]. Nevertheless, during the 1990s, consensus guidelines increasingly advocated use of short-acting b 2 -agonists (SABAs) only as needed for symptom relief [14][15][16].…”

mentioning

confidence: 99%

Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials

Sears

Ottosson²,

Radner³

et al. 2008

Eur Respir J

102

View full text Add to dashboard Cite

The safety of long-acting b 2 -agonist (LABA) treatment in asthma has been questioned following reported increased respiratory deaths when salmeterol was added to usual pharmacotherapy. The aim of this study was to examine whether asthma, cardiac or allcause mortality and morbidity were increased with formoterol use.The analysis included all AstraZeneca randomised controlled parallel-group asthma trials of 3-12-months duration involving formoterol. Risks associated with formoterol use compared with non-LABA treatment, overall and in combination with inhaled corticosteroids (ICS), were assessed using an intention-to-treat analysis of the rates and rate ratios of deaths and serious adverse events (SAEs). The main objective of this study was to compare asthma-related mortality in patients using formoterol and those not using formoterol.There were eight asthma-related deaths (0.34 per 1,000 person-yrs) among 49,906 formoterolrandomised patients (92% using ICS), and two (0.22 per 1,000 person-yrs) among 18,098 patients (83% using ICS) not randomised to formoterol, which was nonsignificant. Asthma-related SAEs (.90% of which were hospitalisations) were significantly fewer among formoterol-randomised patients (0.75 versus 1.10%). There was no increase in asthma-related SAEs with increased daily doses of formoterol (9, 18 or 36 mg). There was no significant difference in cardiac mortality or noncardiac nonasthma-related mortality in formoterol-randomised compared to non-LABAtreated patients. All-cause mortality was similar. In the data set in which all subjects were prescribed ICS at baseline, there were seven asthma-related deaths (0.32 per 1,000 person-yrs) among 46,003 formoterol-randomised patients and one (0.14 per 1,000 person-yrs) among 13,905 patients not randomised to formoterol, which was also nonsignificant.There were few asthma-related or cardiac-related deaths among patients randomised to formoterol, and all differences were nonsignificant compared with non-long-acting b 2 -agonistrandomised patients. However, despite data on .68,000 patients, the power was insufficient to conclude that there was no increased mortality with formoterol. Cardiac-related serious adverse events were not increased, and asthma-related serious adverse events were significantly reduced with formoterol.

show abstract

Regular inhaled salbutamol and asthma control: the TRUST randomised trial

Cited by 87 publications

References 20 publications

Retrospective studies on drug utilization patterns of asthmatics in a Government hospital in Kedah, Malaysia

Retrospective studies on drug utilization patterns of asthmatics in a Government hospital in Kedah, Malaysia

Effect of Kollidon® SR on the release of Albuterol Sulphate from matrix tablets

Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials

Contact Info

Product

Resources

About